Since the first description of the association between chronic kidney disease and heart
disease, many epidemiological studies have confirmed and extended this finding. As …

It is increasingly apparent that not only is a cure for the current worldwide diabetes epidemic
required, but also for its major complications, affecting both small and large blood vessels …

Background The cardiovascular safety and efficacy of many current antihyperglycemic
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …

Wytyczne dotyczące nadciśnienia tętniczego opublikowane w 2013 r. przez Europejskie
Towarzystwo Nadciśnienia Tętniczego (ESH) i Europejskie Towarzystwo Kardiologiczne …

Background To assess potentially elevated cardiovascular risk related to new
antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a …

ESC Guidelines 3039 administrative staff and by the referees and supervisory committees of
the two organizations. It is our hope that this huge effort has generated guidelines that will …

Objective: To review the evidence about the impact of hypoglycemia on patients with
diabetes that has become available since the past reviews of this subject by the American …

Hyperglycemia and insulin resistance are key players in the development of atherosclerosis
and its complications. A large body of evidence suggest that metabolic abnormalities cause …

Background Tracking national progress in diabetes care may aid in the evaluation of past
efforts and identify residual gaps in care. Methods We analyzed data for adults with self …

Background Although inhibitors of the renin–angiotensin–aldosterone system can slow the
progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor …